Narmafotinib

DB18463InvestigationalSmall molecule

Narmafotinib: Overview.

Mechanism: Pharmacologically active on Focal adhesion kinase 1
Curator reviewed
Formula / weight: C₂₈H₃₂F₃N₅O₂ · 527.592 g/mol (avg)
Also known as: 2-(2-(2-((2-methoxy-4-(1-methyl-4-piperidinyl)phenyl)amino)-5-(trifluoromethyl)-4-pyrimidinyl)ethyl)benzeneacetamide · Benzeneacetamide, 2-(2-(2-((2-methoxy-4-(1-methyl-4-piperidinyl)phenyl)amino)-5-(trifluoromethyl)-4-pyrimidinyl)ethyl)-
Code names: AMP-945

Resolves to

Compound

Structure

InChIKeyAWJVIOYPZZZYAX-UHFFFAOYSA-NSMILESCOC1=CC(=CC=C1NC1=NC=C(C(CCC2=CC=CC=C2CC(N)=O)=N1)C(F)(F)F)C1CCN(C)CC1

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Narmafotinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.